<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Ophthalmology Product Guide &#187; Ciprofloxacin HCl Ophthalmic Solution USP</title>
	<atom:link href="http://www.ophthalmologyproductguide.com/blog/tag/ciprofloxacin-hcl-ophthalmic-solution-usp/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.ophthalmologyproductguide.com/blog</link>
	<description>A comprehensive guide to ophthalmology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 12:36:57 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Akorn Announces FDA Approval Of Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%</title>
		<link>http://www.ophthalmologyproductguide.com/blog/2008/12/18/akorn-announces-fda-approval-of-ciprofloxacin-hcl-ophthalmic-solution-usp-03/</link>
		<comments>http://www.ophthalmologyproductguide.com/blog/2008/12/18/akorn-announces-fda-approval-of-ciprofloxacin-hcl-ophthalmic-solution-usp-03/#comments</comments>
		<pubDate>Thu, 18 Dec 2008 12:20:32 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Conjunctiva]]></category>
		<category><![CDATA[Corneal Disease]]></category>
		<category><![CDATA[FDA Approval]]></category>
		<category><![CDATA[Infectious Disease]]></category>
		<category><![CDATA[Akorn]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Ciprofloxacin HCl Ophthalmic Solution USP]]></category>
		<category><![CDATA[corneal ulcers]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://www.ophthalmologyproductguide.com/blog/2008/12/18/akorn-announces-fda-approval-of-ciprofloxacin-hcl-ophthalmic-solution-usp-03/</guid>
		<description><![CDATA[Akorn, Inc. has announced that the U.S. Food and Drug Administration has granted approval for Akorn&#8217;s Abbreviated New Drug Application (ANDA) for Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%. Ciprofloxacin HCl Ophthalmic Solution is indicated for the treatment of infections caused by microorganisms in corneal ulcers and conjunctivitis. Annual sales for Ciprofloxacin HCl Ophthalmic Solution are [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.ophthalmologyproductguide.com/blog/wp-content/uploads/2008/12/akorn.png" vspace="5" width="200" align="left" height="83" hspace="5" /><a href="http://www.akorn.com">Akorn, Inc.</a> has announced that the U.S. Food and Drug Administration has granted approval for Akorn&#8217;s Abbreviated New Drug Application (ANDA) for Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%. Ciprofloxacin HCl Ophthalmic Solution is indicated for the treatment of infections caused by microorganisms in corneal ulcers and conjunctivitis. Annual sales for Ciprofloxacin HCl Ophthalmic Solution are approximately $20 million, according to IMS sales data. Akorn expects to launch Ciprofloxacin in 2009. Of the 20 product approvals received in 2008, 8 were launched in 2008 and 10 are scheduled for launch in the first half of 2009.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ophthalmologyproductguide.com/blog/2008/12/18/akorn-announces-fda-approval-of-ciprofloxacin-hcl-ophthalmic-solution-usp-03/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
